专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2005007642A2 NOVEL AMIDES USEFUL FOR TREATING PAIN 审中-公开
标题翻译：新辅助用于治疗疼痛
公开(公告)号：WO2005007642A2
公开(公告)日：2005-01-27
申请号：PCT/US2004/021836
申请日：2004-07-09
申请人： ABBOTT LABORATORIES , ZHENG, Guo Zhu , BROWN, Brian, S. , TURNER, Sean, C. , WHITE, Tammie, K. , SCHMIDT, Robert, G. , KOENIG, John, R. , LEE, Chih-Hung
发明人： ZHENG, Guo Zhu , BROWN, Brian, S. , TURNER, Sean, C. , WHITE, Tammie, K. , SCHMIDT, Robert, G. , KOENIG, John, R. , LEE, Chih-Hung
IPC分类号： C07D401/04
CPC分类号： C07D401/04 , C07D487/08
摘要： The present invention relates to compounds of formula (I-VII) (I), or a pharmaceutically acceptable salt or prodrug thereof, in which A, L, R 6 , R 7 and R 8 are defined herein. The present invention also relates to methods of trating pain using these compounds and pharmaceutical compositions including these compounds.
摘要翻译：本发明涉及式（I-VII）（I）化合物或其药学上可接受的盐或前药，其中A，L，R 6，R 7和R 8如本文所定义。本发明还涉及使用这些化合物和包括这些化合物的药物组合物来治疗疼痛的方法。

2. 发明申请

WO2005016890A1 FUSED AZABICYCLIC COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR 审中-公开
标题翻译：抑制VANILLOID受体亚型1（VR1）受体的融合的偶氮化合物
公开(公告)号：WO2005016890A1
公开(公告)日：2005-02-24
申请号：PCT/US2004/025109
申请日：2004-08-04
申请人： ABBOTT LABORATORIES , LEE, Chih-Hung , BAYBURT, Erol, K. , DIDOMENICO, Stanley, Jr. , DRIZIN, Irene , GOMTSYAN, Arthur, R. , KOENIG, John, R. , PENNER, Richard, J. , SCHMIDT, Robert, G., Jr. , TURNER, Sean, C. , WHITE, Tammie, K. , ZHENG, Guo Zhu
发明人： BAYBURT, Erol, K. , DIDOMENICO, Stanley, Jr. , DRIZIN, Irene , GOMTSYAN, Arthur, R. , KOENIG, John, R. , PENNER, Richard, J. , SCHMIDT, Robert, G., Jr. , TURNER, Sean, C. , WHITE, Tammie, K. , ZHENG, Guo Zhu
IPC分类号： C07D217/24
CPC分类号： C07D249/08 , C07D209/08 , C07D217/02 , C07D217/22 , C07D217/24 , C07D217/26 , C07D231/12 , C07D231/56 , C07D233/56 , C07D237/28 , C07D401/12 , C07D405/12
摘要： Compounds of Formula (I), are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.
摘要翻译：式（I）化合物是可用于治疗疼痛，炎症性热痛觉过敏，尿失禁和膀胱过度活动的新型VR1拮抗剂。

3. 发明申请

WO2006063178A2 THIENOPYRIDYL COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USES THEREOF 审中-公开
标题翻译：抑制VANILLOID受体亚型1（VR1）的三烯丙基化合物及其用途
公开(公告)号：WO2006063178A2
公开(公告)日：2006-06-15
申请号：PCT/US2005/044500
申请日：2005-12-07
申请人： ABBOTT LABORATORIES , TURNER, Sean, C. , JINKERSON, Tammie, K. , GOMTSYAN, Arthur, R. , LEE, Chih-hung
发明人： TURNER, Sean, C. , JINKERSON, Tammie, K. , GOMTSYAN, Arthur, R. , LEE, Chih-hung
IPC分类号： C07D495/04 , A61K31/4365 , A61P13/10 , A61P29/00
CPC分类号： C07D495/04 , C07D498/04
摘要： The present invention discloses fused thienopyridyl compounds of general formula (I), wherein X 1 -X 6 , R 5 -R 7 , Z 1 and L are as defined in the description. The resent invention also discloses a method for inhibiting the VR1 receptor in mammals using these compounds, a method for controlling pain, urinary incontinence, bladder overactivity, and inflammatory thermal hyperalgesia in mammals, and pharmaceutical compositions including those compounds.
摘要翻译：本发明公开了通式（I）的稠合噻吩并吡啶基化合物，其中X 1 -X 6 -X 6，R 5 -R 7 Z 1，L 1和L如说明书中所定义。本发明还公开了使用这些化合物抑制哺乳动物中的VR1受体的方法，用于控制哺乳动物中的疼痛，尿失禁，膀胱过度活动和炎性热痛觉过敏的方法，以及包括那些化合物的药物组合物。

4. 发明公开

EP1660455A1 FUSED AZABICYCLIC COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR 有权
标题翻译： THE VANILLOIDREZEPTORSUBTYP 1（VR1）简明氮杂双环化合物 - 受体禁止
公开(公告)号：EP1660455A1
公开(公告)日：2006-05-31
申请号：EP04780017.2
申请日：2004-08-04
申请人： ABBOTT LABORATORIES , Lee, Chih-Hung
发明人： BAYBURT, Erol, K. , DIDOMENICO, Stanley, Jr. , DRIZIN, Irene , GOMTSYAN, Arthur, R.; , KOENIG, John, R. , PENNER, Richard, J. , SCHMIDT, Robert, G., Jr. , TURNER, Sean, C. , WHITE, Tammie, K. , ZHENG, Guo Zhu
IPC分类号： C07D217/24 , C07D217/02 , C07D237/28 , C07D217/22 , C07D209/08 , C07D231/56 , C07D217/26 , C07D401/12 , C07D405/12 , C07D403/12 , C07D451/02 , A61K31/47 , A61K31/472 , A61K31/496 , A61K31/5377
CPC分类号： C07D249/08 , C07D209/08 , C07D217/02 , C07D217/22 , C07D217/24 , C07D217/26 , C07D231/12 , C07D231/56 , C07D233/56 , C07D237/28 , C07D401/12 , C07D405/12
摘要： Compounds of Formula (I), are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.

5. 发明申请

WO2010135560A1 MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF 审中-公开
标题翻译： 5-HT受体的调节剂及其使用方法
公开(公告)号：WO2010135560A1
公开(公告)日：2010-11-25
申请号：PCT/US2010/035626
申请日：2010-05-20
申请人： ABBOTT LABORATORIES , AKRITOPOULOU-ZANZE, Irini , BRAJE, Wilfried , DJURIC, Stevan, W. , WILSON, Noel, S. , TURNER, Sean, C. , KRUGER, Albert, W. , RELO, Ana-Lucia , SHEKHAR, Shashank , WELCH, Dennie, S. , ZHAO, Hongyu , GANDARILLA, Jorge , GASIECKI, Alan, F. , LI, Huanqiu , THOMPSON, Christina, M. , ZHANG, Min
发明人： AKRITOPOULOU-ZANZE, Irini , BRAJE, Wilfried , DJURIC, Stevan, W. , WILSON, Noel, S. , TURNER, Sean, C. , KRUGER, Albert, W. , RELO, Ana-Lucia , SHEKHAR, Shashank , WELCH, Dennie, S. , ZHAO, Hongyu , GANDARILLA, Jorge , GASIECKI, Alan, F. , LI, Huanqiu , THOMPSON, Christina, M. , ZHANG, Min
IPC分类号： C07D487/04 , C07D491/04 , C07D495/04 , A61P25/00 , A61K31/551 , A61K31/554 , A61K31/553
CPC分类号： C07D513/04 , C07D487/04 , C07D491/04 , C07D491/044 , C07D495/04 , C07D495/16
摘要： The present application relates to aryl- and heteroaryl-fused decahydropyrroloazepine, octahydrooxepinopyrrole, octahydropyrrolothiazepine dioxide, decahydrocyclohepta[ c ]pyrrole, and octahydrocyclohepta[ c ]pyrrole derivatives of formula (I), wherein R 1 , R 2 , R 3 , R 4 , R 5 , A, Y 1 , Y 2 , and Y 3 are as defined in the specification. The present application also relates to compositions comprising such compounds, processes for making such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.
摘要翻译：本申请涉及式（I）的芳基 - 和杂芳基 - 稠合十氢吡咯并氮平，八氢恶庚英吡咯，八氢吡咯并噻吩二恶烷，十氢环庚三烯并[c]吡咯和八氢环庚三烯并[c]吡咯衍生物，其中R1，R2，R3，R4，R5， Y1，Y2和Y3如说明书中所定义。本申请还涉及包含这些化合物的组合物，制备此类化合物的方法，以及使用这些化合物和组合物治疗疾病状况的方法，以及鉴定这些化合物的方法。

6. 发明申请

WO2006040180A1 AMINOMETHYL SUBSTITUTED BICYCLIC AROMATIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR 审中-公开
标题翻译：适用于治疗多巴胺D3受体调节障碍的氨基甲酸替代双相芳族化合物
公开(公告)号：WO2006040180A1
公开(公告)日：2006-04-20
申请号：PCT/EP2005/011093
申请日：2005-10-14
申请人： ABBOTT GMBH & CO. KG , DRESCHER, Karla , HAUPT, Andreas , UNGER, Liliane , TURNER, Sean, C. , BRAJE, Wilfried , GRANDEL, Roland
发明人： DRESCHER, Karla , HAUPT, Andreas , UNGER, Liliane , TURNER, Sean, C. , BRAJE, Wilfried , GRANDEL, Roland
IPC分类号： C07C317/34 , C07D209/14 , C07D209/62 , C07D235/14 , A61K31/136 , A61P25/00 , A61K31/145 , A61K31/403 , A61K31/407 , A61K31/4174
CPC分类号： C07D471/04 , C07D209/14 , C07D209/62 , C07D235/14
摘要： The present invention relates to an aminomethyl substituted bicyclic aromatic compound of the formula (I) wherein Ar is a cyclic radical selected from the group consisting of phenyl, a 5- or 6-membered C-bound heteroaromatic radical comprising as ring member 1, 2 or 3 heteroatoms which are, independently of each other, selected from O, S and N, and a phenyl ring fused to a saturated or unsaturated 5- or 6-membered carbocyclic or heterocyclic ring, where the heterocyclic ring comprises as ring members 1, 2 or 3 heteroatoms selected from N, O and S and/or 1, 2 or 3 heteroatom-containing groups each independently selected from NR 8 , where R 8 is H, C 1 -C 4 -alkyl, fluorinated C 1 -C 4 -alkyl, C 1 -C 4 -alkylcarbonyl or fluorinated C 1 -C 4 -alkylcarbonyl, and where the cyclic radical Ar may carry 1, 2 or 3 substituents R a , wherein the variable R a has the meanings given in the claims and in the description; X is a covalent bond or N-R 2 , CHR 2 , CHR 2 CH 2 , N or C-R 2 ; Y is N-R 2a , CHR 2a , CHR 2a CH 2 or CHR 2a CH 2 CH 2 ; is a single bond or a double bond; E is CH 2 or NR 3 ; R 1 is H, C 1 -C 4 -alkyl, C 3 -C 4 -cycloalkyl, C 3 -C 4 -cycloalkylmethyl, C 3 -C 4 -alkenyl, fluorinated C 1 -C 4 -alkyl, fluorinated C 3 -C 4 -cycloalkyl, fluorinated C 3 -C 4 -cycloalkylmethyl, fluorinated C 3 -C 4 -alkenyl, formyl or C 1 -C 3 -alkylcarbonyl; R 1a is H, C 1 -C 4 -alkyl, C 3 -C 4 -cycloalkyl, C 3 -C 4 -alkenyl, fluorinated C 1 -C 4 -alkyl, fluorinated C 3 -C 4 -cycloalkyl, fluorinated C 3 -C 4 -alkenyl, R 2 and R 2a each independently are H, CH 3 , CH 2 F, CHF 2 or CF 3 or R 1a and R 2 or R 1a and R 2a together are (CH 2 ) n with n being 1, 2 or 3; R 3 is H or C 1 -C 4 -alkyl; R 4 and R 5 independently of each other are H, C 1 -C 4 -alkyl, fluorinated C 1 -C 4 -alkyl or C 1 -C 4 -alkoxy or may form, together with N, a 4-, 5- or 6-membered saturated or unsaturated ring; R 6 and R 7 independently of each other are H or halogen; and the physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula (I) or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.
摘要翻译：本发明涉及式（I）的氨基甲基取代的双环芳族化合物，其中Ar是选自苯基，5-或6-元C-结合的杂芳族基团的环状基团，其包含作为环成员1,2 或3个彼此独立地选自O，S和N的杂原子和稠合于饱和或不饱和的5-或6-元碳环或杂环的苯环，其中杂环包含作为环成员1， 2或3个选自N，O和S的杂原子和/或1,2或3个含杂原子的基团，各自独立地选自NR 8，其中R 8是H， C 1 -C 4 - 亚烷基，氟化C 1 -C 4 - 烷基，C 1 -C 1-4烷基，C 1 -C 4烷基，C 1 -C 4 - 其中环状基团Ar可以带有1个碳原子的烷基羰基或氟化C 1 -C 4 - 烷基羰基， 2或3个取代基R a a，其中变量R a a具有在声明和说明书; X是共价键或NR 2，CHR 2，CHR 2 CH 2，N或CR ^{2 ; Y是NR 2a，CHR 2，H 2，CH 2，CH 2或CHR 2 O 2， CH _{2 CH _{2 ; 是单键或双键; E是CH 2或NR 3; R 1是H，C 1 -C 4 - 烷基，C 3 -C 4 - C 3 -C 4 - 环烷基甲基，C 3 -C 4 - 亚烷基，C 3 -C 4 - 环烷基，C 3 -C 4 - 氟化C 1 -C 4 - 亚烷基，氟化C 3 -C 4 - 环烷基，氟化C _{-C _{3 - 烷基羰基; R 1a是H，C 1 -C 4 - 烷基，C 3 -C 4烷基， C 3 -C 4 - 亚烷基，氟化C 1 -C 4 - 亚烷基，C 3 -C 4 - 氟化C 3 -C 4 - 环烷基，氟化C 3 -C 4 - 亚烯基，R SUP > 2和R 2a各自独立地为H，CH 3，CH 2，F，CHF 2， >或CF 3或R 1a和R 2或R 1a和R 2a和R 2b 一起是n为1,2或3的（CH 2）2 n。 R 3是H或C 1 -C 4 - 烷基; R 4和R 5彼此独立地为H，C 1 -C 4 - 烷基，氟化C C 1 -C 4 - 烷基或C 1 -C 4 - 烷氧基，或者可以与N， 4-，5-或6-元饱和或不饱和环; R 6和R 7彼此独立地为H或卤素; 及其生理上耐受的酸加成盐。本发明还涉及式（I）化合物或其药学上可接受的盐在制备用于治疗易受多巴胺D3受体配体治疗的医学疾病的药物组合物中的用途。}}}}}

7. 发明申请

WO2006040177A1 6-AMINO(AZA)INDANE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECPTOR 审中-公开
标题翻译：适用于治疗多巴胺D3受体调节症状的6-AMINO（AZA）INDANE化合物
公开(公告)号：WO2006040177A1
公开(公告)日：2006-04-20
申请号：PCT/EP2005/011090
申请日：2005-10-14
申请人： ABBOTT GMBH & CO.KG , DRESCHER, Karla , HAUPT, Andreas , UNGER, Liliane , TURNER, Sean, C. , BRAJE, Wilfried , GRANDEL, Rolan
发明人： DRESCHER, Karla , HAUPT, Andreas , UNGER, Liliane , TURNER, Sean, C. , BRAJE, Wilfried , GRANDEL, Rolan
IPC分类号： C07C311/21 , C07D221/06 , C07D239/38 , C07D333/34 , C07D401/12 , C07D409/12 , A61K31/18 , A61K31/506 , A61P25/18
CPC分类号： C07D239/38 , C07C311/21 , C07C2601/02 , C07C2601/04 , C07C2602/08 , C07D221/06 , C07D333/34 , C07D401/12 , C07D409/12
摘要： The present invention relates to 6-amino(aza)indane compound of the formula (I) Wherein Ar is phenyl or an aromatic 5- or 6-membered C-bound heteroaromatic radical, wherein Ar may carry 1 radical R a and wherein Ar may also carry I or 2 radicals R b ; X is N or CH; E is CR 6 R 7 or NR 3 ; R 1 is C 1 -C 4 -alkyl, C 3 -C4-cycloalkyl, C 3 -C 4 -cycloalkylmethyl, C 3 -C 4 -alkenyl, fluorinated C 1 -C 4 -alkyl, fluorinated C 3 -C 4 -cycloalkyl, fluorinated C 3 -C 4 -cycloalkylmethyl, fluorinated C 3 -C 4 -alkenyl, formyl or C 1 -C 3 -alkylcarbonyl; R 1a is H or R 1a and R 2 or R 1a and R 2a together are (CH 2 ) n with n being 1, 2, 3 or 4; R 2 and R 2a each independently are H, CH 3 , CH 2 F, CHF 2 or CF 3 ; R 3 is H or C,-C4-alkyl; and the physiologically tolerated acid addition salts of these compounds. The invention also relates to pharmaceutical compositions comprising at least one compound of the formula (I) or a pharmaceutically acceptable salt thereof and to a method for treating a medical disorder susceptible to treatment with a dopamine D3 receptor ligand, said method comprising administering an effective amount of at least one compound of the formula (I) or a pharmaceutically acceptable salt thereof.
摘要翻译：本发明涉及式（I）的6-氨基（氮杂）二氢化茚化合物，其中Ar是苯基或芳族5-或6-元C-结合的杂芳族基团，其中Ar可以带有1个基团R a，并且其中Ar还可以携带I或2个基团R b， X为N或CH; E是CR 6，R 7或NR 3; R 1是C 1 -C 4 - 烷基，C 3 -C 4 - 环烷基，C 1 -C 4 - C 3 -C 4 - 环烷基甲基，C 3 -C 4 - 烯基，氟化C 1 - 氟化C 3 -C 4 - 环烷基，氟化C 3 -C 3 - 亚烷基，C 3 - 氟化C 3 -C 4 - 亚烷基，甲酰基或C 1 -C 3烷基， / SUB> - 烷基羰基; R 1a是H或R 1a和R 2或R 1a和R 2a和/或O 2 一起是n为1,2,3或4的（CH 2）2 n， R 2和R 2各自独立地为H，CH 3，CH 2 F，CHF 2 /或CF 3 3; R 3是H或C 1 -C 4 - 烷基; 和这些化合物的生理上耐受的酸加成盐。本发明还涉及包含至少一种式（I）化合物或其药学上可接受的盐的药物组合物和治疗易受多巴胺D3受体配体治疗的医学疾病的方法，所述方法包括施用有效量的至少一种式（I）化合物或其药学上可接受的盐。

8. 发明申请

WO2006040182A1 HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR 审中-公开
标题翻译：适用于治疗多巴胺D3受体调节障碍的异种化合物
公开(公告)号：WO2006040182A1
公开(公告)日：2006-04-20
申请号：PCT/EP2005/011106
申请日：2005-10-14
申请人： ABBOTT GMBH & CO. KG , DRESCHER, Karla , HAUPT, Andreas , UNGER, Liliane , TURNER, Sean, C. , BRAJE, Wilfried , GRANDEL, Roland , HENRY, Christophe , BACKFISCH, Gisela , BEYERBACH, Armin , LUBISCH, Wilfried
发明人： DRESCHER, Karla , HAUPT, Andreas , UNGER, Liliane , TURNER, Sean, C. , BRAJE, Wilfried , GRANDEL, Roland , HENRY, Christophe , BACKFISCH, Gisela , BEYERBACH, Armin , LUBISCH, Wilfried
IPC分类号： C07D207/09 , C07D401/12 , C07D405/12 , C07D409/12 , C07D401/04 , C07D403/04 , C07D413/12 , C07D205/04 , C07D413/10 , C07D413/14 , C07D211/28 , A61K31/397 , A61K31/445 , A61P25/16
CPC分类号： C07D413/14 , C07D205/04 , C07D207/09 , C07D211/28 , C07D401/04 , C07D401/12 , C07D403/04 , C07D405/12 , C07D409/12 , C07D413/10 , C07D413/12
摘要： The invention relates to compounds of the formula (I) wherein n is 0, 1 or 2; G is CH 2 or CHR 3 ; R 1 is H, C,-C 6 -alkyl, C,-C 6 -alkyl substituted by C 3 -C 6 -cycloalkyl, C l -C 6 -hydroxyalkyl, fluorinated C,-C 6 -alkyl, C 3 -C 6 -cycloalkyl, fluorinated C 3 -C 6 -cycloalkyl, C 3 -C 6 alkenyl, fluorinated C 3 -C 6 -alkenyl, formyl, acetyl or propionyl; R 2 , R 3 and R 4 are, independently of each other, H, methyl, fluoromethyl, difluoromethyl, or trifluoromethyl; A is phenylene, pyridylene, pyrimidylene, pyrazinylene, pyridazinylene or thiophenylene, which can be substituted by one ore more substituents selected from halogen, methyl, methoxy and CF 3 ; E is NR 5 or CH 2 , wherein R 5 is H or C 1 -C 3 -alkyl; Ar is a cyclic radical selected from the group consisting of phenyl, a 5- or 6- membered heteroaromatic radical comprising as ring members 1, 2 or 3 heteroatoms selected from N, O and S and a phenyl ring fused to a saturated or unsaturated 5- or 6-membered carbocyclic or heterocyclic ring, where the heterocyclic ring comprises as ring members 1, 2 or 3 heteroatoms selected from N, O and S and/or 1, 2 or 3 heteroatom-containing groups each independently selected from NR 8 , where R 8 is H, C 1 -C 4 -alkyl, fluorinated C 1 -C 4 -alkyl, C 1 -C 4 alkylcarbonyl or fluorinated C 1 -C 4 -alkylcarbonyl, and where the cyclic radical Ar may carry 1, 2 or 3 substituents R a , wherein the variable R a has the meanings given in the claims and in the description; and physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.
摘要翻译：本发明涉及式（I）化合物，其中n为0,1或2; G是CH

9. 发明申请

WO2006040179A1 AMINOETHYLAROMATIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR 审中-公开
标题翻译：适用于治疗多巴胺D3受体调节障碍的氨基甲醛化合物
公开(公告)号：WO2006040179A1
公开(公告)日：2006-04-20
申请号：PCT/EP2005/011092
申请日：2005-10-14
申请人： ABBOTT GMBH & CO. KG , DRESCHER, Karla , HAUPT, Andreas , UNGER, Liliane , TURNER, Sean, C. , BRAJE, Wilfried , GRANDEL, Roland
发明人： DRESCHER, Karla , HAUPT, Andreas , UNGER, Liliane , TURNER, Sean, C. , BRAJE, Wilfried , GRANDEL, Roland
IPC分类号： C07C311/29 , C07C311/21 , C07D213/76 , C07D207/09 , C07C317/22 , C07C317/14 , A61K31/18 , A61K31/44 , A61P25/18
CPC分类号： C07D213/76 , C07C311/21 , C07C311/29 , C07C2601/02 , C07D207/09
摘要： The present invention relates to aromatic compounds of the formula (I) wherein Ar is phenyl or an aromatic 5- or 6-membered C-bound heteroaromatic radical, wherein Ar may carry 1 radical R a and wherein Ar may also carry 1 or 2 radicals R b ; X is N or CH; E is CR 6 R 7 or NR 3 ; R 1 is C 1 -C 4 -alkyl, C 3 -C 4 -cycloalkyl, C 3 -C 4 -cycloalkylmethyl, C 3 -C 4 -alkenyl, fluorinated C l -C 4 -alkyl, fluorinated C 3 -C 4 -cycloalkyl, fluorinated C 3 -C 4 -cycloalkylmethyl, fluorinated C 3 -C 4 -alkenyl, formyl or C 1 -C 3 -alkylcarbonyl; R 1a is H, C 1 -C 4 -alkyl, C 3 -C 4 -cycloalkyl, C 3 -C 4 -cycloalkylmethyl, C 3 -C 4 -alkenyl, fluorinated C 1 -C 4 -alkyl, fluorinated C 3 -C 4 -cycloalkyl, fluorinated C 3 -C 4 -cycloalkylmethyl, fluorinated C 3 -C 4 -alkenyl, or R 1a and R 2 together are (CH 2 ) n with n being 2, 3 or 4, or R 1a and R 2a together are (CH 2 ) n with n being 2, 3 or 4; R 2 and R 2a are independently of each other H, C 1 -C 4 -alkyl or fluorinated C 1 -C 4 -alkyl or R 2a and R 2 together are (CH 2 ) m with m being 1, 2, 3, 4 or 5; R 3 is H or C 1 -C 4 -alkyl; R 6 , R 7 independently of each other are selected from H, fluorine, C 1 -C 4 -alkyl and fluorinated C 1 -C 4 -alkyl or together form a moiety (CH 2 ) p with p being 2, 3, 4 or 5; and the physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula (I) or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D 3 receptor ligand.
摘要翻译：本发明涉及式（I）的芳族化合物，其中Ar是苯基或芳族5-或6-元C-结合杂芳族基团，其中Ar可以携带1个基团R 1

10. 发明申请

WO2006040176A1 AZABICYCLOHEPTYL COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR 审中-公开
标题翻译：适用于治疗多巴胺D3受体调节紊乱的化学物质
公开(公告)号：WO2006040176A1
公开(公告)日：2006-04-20
申请号：PCT/EP2005/011089
申请日：2005-10-14
申请人： ABBOTT GMBH & CO. KG , DRESCHER, Karla , HAUPT, Andreas , UNGER, Liliane , TURNER, Sean, C. , BRAJE, Wilfried , GRANDEL, Roland
发明人： DRESCHER, Karla , HAUPT, Andreas , UNGER, Liliane , TURNER, Sean, C. , BRAJE, Wilfried , GRANDEL, Roland
IPC分类号： C07D209/52 , C07D403/12 , C07D405/12 , C07D409/12 , A61K31/00 , A61P25/28
CPC分类号： C07D401/12 , C07D209/52 , C07D403/12 , C07D405/12 , C07D409/12 , C07D413/12 , C07D417/12
摘要： The present invention relates to a compound of the formula (I) wherein R 1 is H, C 1 -C 6 -alkyl which may be substituted by C 3 -C 6 -cycloalkyl, fluorinated C 1 -C 6 -alkyl, C 3 -C 6 -cycloalkyl, fluorinated C 3 -C 6 -cycloalkyl, C 3 -C 6 -alkenyl, fluorinated C 3 -C 6 -alkenyl, formyl, acetyl or propionyl; A is phenylene, pyridylene, pyrimidylene, pyrazinylene, pyridazinylene or thiophenylene, which can be substituted by one ore more substituents selected from halogen, methyl, methoxy and CF 3 ; E is NR 5 or CH 2 , wherein R 5 is H or C 1 -C 3 -alkyl; Ar is a cyclic radical selected from the group consisting of phenyl, a 5- or 6-membered heteroaromatic radical comprising as ring members 1, 2 or 3 heteroatoms selected from N, O and S and a phenyl ring fused to a saturated or unsaturated 5- or 6-membered carbocyclic or heterocyclic ring, where the heterocyclic ring comprises as ring members 1, 2 or 3 heteroatoms selected from N, O and S and/or 1, 2 or 3 heteroatom-containing groups each independently selected from NR 8 , where R 8 is H, C 1 -C 4 -alkyl, fluorinated C 1 -C 4 -alkyl, C 1 -C 4 -alkylcarbonyl or fluorinated C 1 -C 4 -alkylcarbonyl, and where the cyclic radical Ar may carry 1, 2 or 3 substituents R a ; wherein the variable R a has the meanings given in the claims and in the description; and physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula (I) or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.
摘要翻译：本发明涉及式（I）化合物，其中R

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式